NHT
DGX icon

New Hampshire Trust’s Quest Diagnostics DGX Stock Holding History

New Hampshire Trust’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$789K Buy
3,723
+8
+0.2% +$1.57K 0.15% 94
2026
Q1 		$728K Buy
3,715
+111
+3% +$21.6K 0.15% 91
2025
Q4 		$625K Sell
3,604
-500
-12% -$91K 0.12% 106
2025
Q3 		$782K Buy
4,104
+371
+10% +$65.8K 0.15% 93
2025
Q2 		$671K Buy
3,733
+151
+4% +$26.2K 0.14% 94
2025
Q1 		$606K Buy
3,582
+86
+2% +$14.1K 0.14% 95
2024
Q4 		$527K Buy
3,496
+10
+0.3% +$1.55K 0.11% 109
2024
Q3 		$541K Sell
3,486
-11
-0.3% -$1.64K 0.12% 110
2024
Q2 		$479K Sell
3,497
-40
-1% -$5.48K 0.11% 113
2024
Q1 		$471K Buy
3,537
+569
+19% +$73.8K 0.11% 116
2023
Q4 		$409K Sell
2,968
-73
-2% -$9.6K 0.1% 121
2023
Q3 		$371K Sell
3,041
-67
-2% -$8.93K 0.1% 119
2023
Q2 		$437K Buy
3,108
+38
+1% +$5.24K 0.11% 114
2023
Q1 		$434K Sell
3,070
-39
-1% -$5.58K 0.12% 112
2022
Q4 		$486K Buy
+3,109
New +$447K 0.13% 110

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

New Hampshire Trust's DGX Position: Q2 2026 in Review

New Hampshire Trust increased its Quest Diagnostics (DGX) stake by 0.22% in Q2 2026, buying an estimated $1.57K and bringing the position to 3,723 shares worth $789K. The position accounts for 0.15% of the portfolio, ranked #94.

New Hampshire Trust first reported a position in DGX in Q4 2022 and has held it in 15 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • New Hampshire Trust held 3,723 shares of Quest Diagnostics worth $789K as of Q2 2026.
  • New Hampshire Trust bought 8 Quest Diagnostics shares in Q2 2026, an estimated $1.57K.
  • Quest Diagnostics made up 0.15% of New Hampshire Trust's portfolio in Q2 2026, its #94 holding.
  • New Hampshire Trust first reported a position in Quest Diagnostics in Q4 2022 and has held it in 15 quarters since.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on New Hampshire Trust's 13F filing for Q2 2026, filed 27 Jul 2026.